| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 02/27/2003 | US20030040483 Compounds with growth hormone releasing properties |
| 02/27/2003 | US20030040461 Providing a cell expressing Bruton's Tyrosine Kinase; contacting cell expressing Bruton's Tyrosine Kinase with a test compound; determining whether test compound modulates the activity of Bruton's Tyrosine Kinase |
| 02/27/2003 | US20030039999 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | US20030039656 Modified reoviral therapy |
| 02/27/2003 | US20030039654 Amino acid sequence of parathyroid hormone/parathyroid hormone related protein modulating domains and a vehicle for to stimulate renal calcium reabsorption |
| 02/27/2003 | US20030039627 Administering to the patient a therapeutically effective amount of an amine containing polymer |
| 02/27/2003 | US20030039626 Fat-binding polymers |
| 02/27/2003 | US20030039611 Selectively binds to antigen to cause cell impairment |
| 02/27/2003 | CA2458643A1 Nucleic-acid associated proteins |
| 02/27/2003 | CA2458068A1 Methods and compositions for treating apoptosis associated disorders |
| 02/27/2003 | CA2457789A1 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides |
| 02/27/2003 | CA2457783A1 Oligonucleotide compositions and their use to induce apoptosis |
| 02/27/2003 | CA2457644A1 Sesquiterpenoid derivatives having adipocyte differentiation inhibitory effect |
| 02/27/2003 | CA2457632A1 Identification and isolation of somatic stem cells and uses thereof |
| 02/27/2003 | CA2457453A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | CA2457452A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | CA2457055A1 Process for producing 1,4-dihydroxy-2-naphthoic acid |
| 02/27/2003 | CA2457041A1 Novel combination |
| 02/27/2003 | CA2456868A1 Inhibitors of polyq-aggregation |
| 02/27/2003 | CA2456150A1 Selective estrogen receptor modulators |
| 02/27/2003 | CA2454671A1 Pharmaceutical composition for nasal delivery of estradiol and norethisterone |
| 02/27/2003 | CA2453647A1 1-alkyl 0r 1-cycloalkyltriazolo¬4,3-a|quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | WO2002020467A1 Novel crystals of n-hydroxy-2(s)-methyl-5-ethoxymethoxy -4(s)-[n-(4-phenoxyphenylcarbonyl)amino]pentanamide, process for their production and medicines containing the crystals as the active ingredient |
| 02/26/2003 | EP1286165A2 Neuropeptide receptor and uses thereof |
| 02/26/2003 | EP1285922A1 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| 02/26/2003 | EP1285916A1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels |
| 02/26/2003 | EP1285664A2 Methods of increasing lean tissue mass using OB protein compositions |
| 02/26/2003 | EP1285659A1 Use of clarithromycin compositions in the manufacture of a medicament for the treatment of arthritis deformans |
| 02/26/2003 | EP1285074A1 Rh116 polypeptides and its fragments and polynucleotides encoding said polypeptides and therapeutic uses |
| 02/26/2003 | EP1285063A1 Anti-angiogenic polypeptides |
| 02/26/2003 | EP1285001A1 Methods for identifying modulators of the interaction between lap (latency associated peptide) and integrin alpha.v.beta.3 and medical use thereof |
| 02/26/2003 | EP1284977A1 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 02/26/2003 | EP1284973A2 Inhibitors of alpha l beta 2 mediated cell adhesion |
| 02/26/2003 | EP1284963A1 Novel calcium receptor active molecules and method for preparing same |
| 02/26/2003 | EP1284958A1 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using aminoidane derivatives |
| 02/26/2003 | EP1284956A1 Il-8 receptor antagonists |
| 02/26/2003 | EP1284952A1 Substituted chalcones as therapeutic compounds |
| 02/26/2003 | EP1284754A1 Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts |
| 02/26/2003 | EP1284753A2 Combination of growth hormone secretagogues and antidepressants |
| 02/26/2003 | EP1284750A1 Pharmaceutical composition |
| 02/26/2003 | EP1284748A1 Treatment of damaged connective tissue |
| 02/26/2003 | EP1284747A2 Compositions and methods for achieving immune suppression |
| 02/26/2003 | EP1284740A2 Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono- and disaccharide-based compounds |
| 02/26/2003 | EP1284739A1 Composition and method for intervening neuronal death using sulfasalazine |
| 02/26/2003 | EP1284724A1 Method of preparing alkylated salicylamides via a dicarboxylate intermediate |
| 02/26/2003 | EP1284717A1 Formulation based on heparin, glycosaminoglycan or heparinoid, use of the formulation and the formulation base |
| 02/26/2003 | EP1150976B1 3-(thio-substituted amido)-lactams useful as inhibitors of matrix metalloproteinase |
| 02/26/2003 | EP1100797B1 Heterocyclic compounds as inhibitors of rotamase enzymes |
| 02/26/2003 | EP1042297B1 Carboxyl acid substituted heterocycles as metalloproteinase inhibitors |
| 02/26/2003 | EP1032386B1 Use of oxazolidinone derivatives for treating arthritis |
| 02/26/2003 | EP0934304B1 2-pyrimidineamine derivatives and processes for their preparation |
| 02/26/2003 | EP0929571B1 4-substituted-3-(2-amino-2-cycloalkyl methyl)-acetamido azetidin-2-one derivatives as cysteine proteinase regulators |
| 02/26/2003 | EP0822986B1 Antagonists of human interleukin-6 that are totally incapable of binding gp 130, and their use in the preparation of pharmaceutical compounds |
| 02/26/2003 | CN1399678A Human Enzymes of metalloprotease family |
| 02/26/2003 | CN1399644A Novel human G-Protein coupled receptor |
| 02/26/2003 | CN1399633A 嘧啶衍生物 Pyrimidine derivatives |
| 02/26/2003 | CN1399631A Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
| 02/26/2003 | CN1399622A Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 02/26/2003 | CN1399573A Use of phthalazine derivatives |
| 02/26/2003 | CN1399559A Micro-cluster liquids and methods of making and using them |
| 02/26/2003 | CN1399550A Use of flupirtine for alleviating pain caused by degenerative joint diseases in dogs and cats |
| 02/26/2003 | CN1398896A Hybrid peptide with vascularization inhibiting activity |
| 02/26/2003 | CN1398861A Prepn and application in preparing medicine of Fraxinus general coumarin |
| 02/26/2003 | CN1398645A Composite transplant containing concanavalin A and its prepn and application |
| 02/26/2003 | CN1398619A Chinese medicine for treating osteonecrosis and osteomyelitis and its prepn |
| 02/26/2003 | CN1398618A Chinese medicine capsule for treating rbeumatism and protrusion of lumber interverterbral disc |
| 02/26/2003 | CN1398603A Plaster for treating pain in neck, shoulder, waist and leg and its prepn process |
| 02/26/2003 | CN1398589A Medicinal use and prepn process of general ketosteroid of Tinospora Hainanesis |
| 02/26/2003 | CN1398584A Slow-releasing bFGF-PLGA microball and its prepn and use |
| 02/26/2003 | CN1102054C Medical wine for treating rheumatoid arthritis |
| 02/26/2003 | CA2419744A1 A novel crystal of n-hydroxy-2(s)-methyl-5-ethoxymethoxy-4(s)-¬n-(4-phenoxyphenylcarbonyl)amino|pentanamide and a method for the preparation thereof and a pharmaceutical agent comprising the same as active ingredient |
| 02/25/2003 | US6525102 Increasing storage stability of interleukin-2 by incorporating free base form arginine and succinic acid |
| 02/25/2003 | US6525072 Prevention and treatment of cellular disorders such as cancer |
| 02/25/2003 | US6525070 Bipiperidine derivatives as modulators of CCR3 activity and as H1 antagonists |
| 02/25/2003 | US6525067 Substituted heterocyclic derivatives |
| 02/25/2003 | US6525059 Substituted pyrazoles as p38 kinase inhibitors |
| 02/25/2003 | US6525058 1-ethyl methylester 4-((3- (p-(carboxyamidino)phenyl) -2-oxo-5-oxazolidinyl)methyl)-1-piperazineacetate; Gantofiban; antagonistic action to Glycoprotein GPIIb/IIIa receptor; oily base; gantofiban citrate |
| 02/25/2003 | US6525052 Compounds useful as reversible inhibitors of cysteine proteases |
| 02/25/2003 | US6525051 For treating cytokine-induced hypotension, inflammatory bowel disease, cerebral ischemia, arthritis, adult respiratory distress syndrome, asthma |
| 02/25/2003 | US6525047 Which are growth hormone secretogogues and increase the level of endogenous growth hormone; treating osteoporosis, congestive heart failure, frailty associated with aging, obesity; accelerating bone fracture repair |
| 02/25/2003 | US6525046 Aromatic heterocyclic compounds as antiinflammatory agents |
| 02/25/2003 | US6525036 Compounds and compositions as protease inhibitors |
| 02/21/2003 | WO2002020462A1 Benzoic acid derivatives and drugs containing the same as the active ingredient |
| 02/21/2003 | WO2002016328A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | WO2002016323A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | CA2420208A1 Biphenyl derivatives and their use as integrin inhibitors |
| 02/21/2003 | CA2420205A1 Biphenyl derivatives and the use thereof as integrin inhibitors |
| 02/21/2003 | CA2419722A1 Benzoic acid derivatives and drugs containing the same as the active ingredient |
| 02/20/2003 | WO2003014731A2 The natural ligand for orphan g protein coupled receptor gpr86 and methods of use |
| 02/20/2003 | WO2003014702A2 Uses of mammalian cytokine; related reagents |
| 02/20/2003 | WO2003014359A2 A fusion protein |
| 02/20/2003 | WO2003014309A2 Interleukin-1 receptors in the treatment of diseases |
| 02/20/2003 | WO2003014294A2 Tacis and br3 polypeptides and uses thereof |
| 02/20/2003 | WO2003014287A1 Hops extracts, method for the production and use |
| 02/20/2003 | WO2003014163A1 Anti-idiotypic antibodies of hla class i molecules and the use thereof in the preparation of compositions that are designed to inhibit vascular activation |
| 02/20/2003 | WO2003014124A1 Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid derivatives serving as nmda antagonists |
| 02/20/2003 | WO2003014111A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 02/20/2003 | WO2003014101A1 Hydroxamic acid derivatives |
| 02/20/2003 | WO2003014098A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |
| 02/20/2003 | WO2003014092A1 Arylpiperazines and arylpiperidines and their use as metalloproteinase inhibiting agents |